CV Safety Requirements For Motility Drugs Could Take Indication-Centric Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
At a Nov. 17 meeting on 5-HT4 receptor agonists, FDA will ask advisory committee members whether an increased cardiovascular risk would be acceptable depending upon the context of use and whether sponsors need to conduct a dedicated CV study either before or after approval.
You may also be interested in...
GI Motility Agents Do Not Need Dedicated CV Safety Studies, Panel Says
FDA’s Gastrointestinal Drugs Advisory Committee overwhelmingly opposes CV-specific studies for the class of 5-HT4 receptor agonists, but says Phase III trials should include patients at high risk for events.
Orexigen Resurrects Contrave With New Trial Agreement With FDA
The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.